Eqitx appoints chief executive officer
Wednesday, 01 September, 2004
Melbourne-based Equitx (ASX:EQX) has appointed former Agenix vice president Sue Parry-Jones as chief executive officer.
“Sue’s experience in new product development and commercialisation at a number of large pharmaceutical companies including Schering-Plough and Bristol-Myers Squibb, together with her biotechnology industry experience at Agenix and Amgen, have given her an ideal mix of skills to progress the development of our VacTX novel vaccine and ZingoTX Gingerol projects,” said Eqitx Chairman Mr Sol Majteles in a statement. Parry-Jones was most recently vice president of Molecular Diagnostic Imaging at Agenix.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
